Bulletin of RSMU

OPINION

The use of monoclonal antibodies in autoimmunity treatment

Merzlyak EM^1,2, Syrko DS², Musatkina EA², Israelson MA^1,2

¹ Group of structural Organization of T-cell Immunity, Department of Adaptive Immunity Genomics, Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Moscow

² Department of Molecular Technologies, Institute of Translational Medicine, Pirogov Russian National Research Medical University, Moscow

Correspondence should be addressed: Ekaterina M. Merzlyak
Miklouho-Maclay 16/10, Moscow, 117997; ur.liam@99niretake

About paper

Funding: this work was supported by the Ministry of Science and Higher Education of the Russian Federation (ID RFMEFI60716X0158).

Received: 2018-12-06 Accepted: 2018-12-27 Published online: 2019-01-01

No data available...

Link to the next paper will be sent to the indicated e-mail's:

OPINION The use of monoclonal antibodies in autoimmunity treatment

Merzlyak EM, Syrko DS, Musatkina EA, Israelson MA

Published in "Bulletin of RSMU" 6, 2018

I want to receive a copy of this message

Vancouver style

Merzlyak EM, Syrko DS, Musatkina EA, Israelson MA. The use of monoclonal antibodies in autoimmunity treatment. Bulletin of RSMU. 2018; (6): 150–4. DOI: 10.24075/brsmu.2018.094

Harvard style

Merzlyak, E. M., Syrko, D. S., Musatkina, E. A. and Israelson, M. A. (2018), "The use of monoclonal antibodies in autoimmunity treatment", Bulletin of RSMU, no. 6, p. 150–154. DOI: 10.24075/brsmu.2018.094

Remember me

Forgot password?

I accept Editorial Policies of the journal

Archive

2018 / 06

OPINION

The use of monoclonal antibodies in autoimmunity treatment